Ramsudha Narala, MD
Ophthalmology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 23
- 5 carriers
- Office
- 1
Offices
1 location · County of Santa Clara · 1,000 clinicians in this group
Looking this up.
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
23 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Narala’s office at (408) 885-5000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
23 of 23 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A147844 · Current
Licensed to practise in California · since 2017 · expires 2028-08-31 · Saint Louis University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Original Medicare doctor bills
$50,906
Medicare paid this office $50,906 for 200 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection of drug into eye | 61 | $15,475 | $94 |
| Established patient complete exam of visual system | 101 | $9,746 | $70 |
| Imaging of retina | 185 | $7,240 | $21 |
| Established patient problem focused exam of visual system | 81 | $6,008 | $42 |
| Return visit (30+ min) | 45 | $2,729 | $52 |
See all 6 services
| Injection of drug into eye | 61 | $15,475 | $94 |
| Established patient complete exam of visual system | 101 | $9,746 | $70 |
| Imaging of retina | 185 | $7,240 | $21 |
| Established patient problem focused exam of visual system | 81 | $6,008 | $42 |
| Return visit (30+ min) | 45 | $2,729 | $52 |
| Photography of the retina | 24 | $460 | $17 |
Who their Medicare patients are
200 Original Medicare patients in 2024. Average age 71 · Under 65 22% · 85 and older 9% · Women 50% · Also on Medicaid 82% · Health risk score 2.42. Sicker patients than 9 in 10 peers; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 75% · Diabetes 73% · Chronic kidney disease 37% · Coronary heart disease 25% · Heart failure 25% · Depression 13% · Atrial fibrillation 11% · Cancer 10% · Stroke 10% · COPD 6% · Dementia 6%.
The office billed $695,224, Medicare allowed $70,451 and paid $50,906; for 922 services of 21 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 200 | 922 | 71 | 2.42 | $695,224 | $50,906 |
| 2023 | 135 | 582 | 70 | 2.43 | $459,998 | $33,685 |
| 2022 | 212 | 771 | 70 | 2.40 | $608,250 | $58,626 |
| 2021 | 329 | 1,925 | 74 | 1.57 | $986,317 | $288,198 |
| 2020 | 282 | 1,426 | 76 | 2.08 | $759,861 | $201,958 |
| 2019 | 63 | 83 | 73 | 1.41 | $31,254 | $5,105 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Injection of drug into eye | 52 | $9,023 | $90 |
| Return visit (30+ min) | 84 | $8,412 | $71 |
| Imaging of retina | 130 | $4,704 | $20 |
| Established patient problem focused exam of visual system | 64 | $4,314 | $43 |
2022: 8 services
| Return visit (30+ min) | 114 | $12,610 | $82 |
| Injection of drug into eye | 58 | $11,974 | $97 |
| Imaging of retina | 144 | $4,920 | $23 |
| Established patient problem focused exam of visual system | 73 | $4,677 | $47 |
| Injection of drug into eye | 17 | $1,575 | $93 |
| Return visit (30+ min) | 24 | $528 | $21 |
| Imaging of retina | 41 | $507 | $11 |
| Established patient complete exam of visual system | 12 | $337 | $28 |
2021: 15 services
| Injection, aflibercept, 1 mg | 19 | $133,984 | None |
| Return visit (30+ min) | 132 | $27,540 | $112 |
| Injection of drug into eye | 55 | $21,635 | $102 |
| Imaging of retina | 270 | $18,698 | $36 |
| New patient visit (45+ min) | 124 | $16,489 | $133 |
| Established patient complete exam of visual system | 83 | $14,891 | $109 |
| Injection, bevacizumab, 10 mg | 31 | $5,679 | None |
| Return visit (30+ min) | 29 | $3,852 | $82 |
| New patient complete exam of visual system | 22 | $2,546 | $116 |
| 2d ultrasound scan of eye tissue and structures | 35 | $2,268 | $44 |
| Established patient problem focused exam of visual system | 16 | $1,644 | $82 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 14 | $1,520 | $109 |
| Imaging of retina | 25 | $881 | $21 |
| Photography of the retina | 19 | $615 | $31 |
| Extended exam of the back part of the eye with optic nerve drawing | 24 | $330 | $14 |
2020: 13 services
| Injection, aflibercept, 1 mg | 43 | $97,776 | None |
| Established patient complete exam of visual system | 119 | $15,777 | $111 |
| Injection of drug into eye | 108 | $15,579 | $91 |
| Injection, ranibizumab, 0.1 mg | 11 | $13,758 | None |
| Imaging of retina | 242 | $12,656 | $36 |
| Established patient problem focused exam of visual system | 91 | $10,444 | $80 |
| New patient complete exam of visual system | 82 | $9,661 | $118 |
| Compounded drug, not otherwise classified | 32 | $3,184 | None |
| Injection, bevacizumab, 10 mg | 26 | $2,602 | None |
| 2d ultrasound scan of eye tissue and structures | 27 | $1,900 | $44 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 14 | $1,281 | $85 |
| Short return visit (20+ min) | 21 | $800 | $38 |
| Extended exam of the back part of the eye with optic nerve drawing | 27 | $386 | $14 |
2019: 3 services
| Short return visit (20+ min) | 20 | $869 | $43 |
| Exam of retinal blood vessels using a special camera after injection of a dye | 15 | $616 | $41 |
| Imaging of retina | 11 | $266 | $24 |
Medicaid work
$31,792 in 2024
Medicaid paid $31,792 for 4,796 billed services this clinician did in 2024, up to 190 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Intravitreal injection of a pharmacologic agent (separate procedure) | 876 | $14,213 |
| Aflibercept injection | 56 | $8,872 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 1,959 | $3,392 |
| Return visit (30+ min) | 93 | $1,992 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 836 | $1,027 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 459 | $1,020 |
| Service | 23 | $957 |
| TREATMENT X10SV RETINOPATHY | 26 | $103 |
| INTRM OPH EXAM NEW PATIENT | 12 | $98 |
| Service | 284 | $62 |
| FUNDUS PHOTOGRAPHY W/INTERPRETATION & REPORT | 50 | $53 |
| Bevacizumab injection | 15 | $4 |
| 2024 | 4,796 | 13 | 190 | $31,792 |
| 2023 | 2,572 | 6 | 152 | $20,128 |
| 2022 | 1,800 | 4 | 122 | $17,170 |
| 2021 | 772 | 6 | 42 | $25,218 |
| 2020 | 29 | 1 | 15 | $476 |
See the largest Medicaid services in earlier years
2023
| Intravitreal injection of a pharmacologic agent (separate procedure) | 478 | $14,093 |
| Return visit (30+ min) | 182 | $2,283 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 722 | $1,980 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 1,102 | $1,759 |
| Injection, bevacizumab, 10 mg | 25 | $13 |
| Service | 63 | $0 |
2022
| Intravitreal injection of a pharmacologic agent (separate procedure) | 403 | $12,848 |
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 650 | $2,015 |
| Ophthalmological services: medical examination and evaluation, with initiation or continuation of diagnostic and treatment program; intermediate, established patient | 609 | $1,581 |
| Return visit (30+ min) | 138 | $726 |
2021
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 473 | $8,358 |
| Intravitreal injection of a pharmacologic agent (separate procedure) | 45 | $6,632 |
| New patient visit (45+ min) | 120 | $4,728 |
| Return visit (30+ min) | 88 | $3,733 |
| Injection, bevacizumab, 10 mg | 16 | $1,052 |
| OPH SVCS MEDICAL XM&EVAL COMPRE EST PT 1/>VST | 30 | $715 |
2020
| Computerized ophthalmic diagnostic imaging (eg, optical coherence tomography [OCT]), posterior segment, with interpretation and report, unilateral or bilateral; retina | 29 | $476 |
Drugs they prescribed that Part D paid
$5,403
Pharmacies billed $5,403 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 105) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
69 generic and 36 brand-name prescriptions · $5,403 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Prednisolone Acetate | 24 | $734 | $31 |
| Timolol Maleate | 21 | $236 | $11 |
| Brimonidine | 15 | $233 | $16 |
| Latanoprost | 13 | $137 | $11 |
Year by year
| 2024 | 105 | 35 | 0% (0) | 34% | $5,403 |
| 2023 | 103 | 32 | 0% (0) | 16% | $2,287 |
| 2022 | 86 | 41 | None | 35% | $4,005 |
| 2021 | 228 | 64 | None | 46% | $14,136 |
| 2020 | 184 | 57 | 0% (0) | 39% | $12,675 |
| 2019 | 128 | 60 | None | 46% | $16,087 |
| 2018 | 142 | 42 | 0% (0) | 39% | $12,308 |
| 2017 | 208 | 49 | 0% (0) | 35% | $9,715 |
| 2016 | 227 | 52 | 0% (0) | 42% | $15,369 |
| 2015 | 163 | 45 | 0% (0) | 39% | $10,677 |
| 2014 | 17 | 11 | None | None | $505 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Prednisolone Acetate | 14 | $553 | $40 |
| Olopatadine | 19 | $435 | $23 |
| Brimonidine | 21 | $420 | $20 |
| Latanoprost | 21 | $258 | $12 |
2022: 2 drugs
| Prednisolone Acetate | 17 | $740 | $44 |
| Latanoprost | 33 | $349 | $11 |
2021: 6 drugs
| Prednisolone Acetate | 55 | $2,400 | $44 |
| Olopatadine | 29 | $2,031 | $70 |
| Brimonidine | 13 | $1,091 | $84 |
| Dorzolamide-Timolol | 18 | $952 | $53 |
| Atropine Sulfate | 16 | $859 | $54 |
| Latanoprost | 26 | $163 | $6 |
2020: 6 drugs
| Olopatadine | 39 | $1,556 | $40 |
| Prednisolone Acetate | 30 | $1,319 | $44 |
| Moxifloxacin | 15 | $614 | $41 |
| Ketorolac Tromethamine | 16 | $238 | $15 |
| Latanoprost | 18 | $176 | $10 |
| Ofloxacin | 11 | $154 | $14 |
2019: 3 drugs
| Prednisolone Acetate | 27 | $1,501 | $56 |
| Olopatadine | 12 | $554 | $46 |
| Latanoprost | 17 | $166 | $10 |
2018: 5 drugs
| Restasis | 12 | $6,542 | $545 |
| Olopatadine | 20 | $1,543 | $77 |
| Prednisolone Acetate | 12 | $658 | $55 |
| Dorzolamide-Timolol | 13 | $274 | $21 |
| Latanoprost | 21 | $195 | $9 |
2017: 5 drugs
| Brimonidine | 35 | $1,962 | $56 |
| Olopatadine | 13 | $1,789 | $138 |
| Prednisolone Acetate | 32 | $1,440 | $45 |
| Latanoprost | 68 | $684 | $10 |
| Timolol Maleate | 16 | $205 | $13 |
2016: 7 drugs
| Lumigan | 19 | $3,039 | $160 |
| Pataday | 15 | $2,369 | $158 |
| Prednisolone Acetate | 27 | $1,726 | $64 |
| Latanoprost | 65 | $613 | $9 |
| Brimonidine | 20 | $257 | $13 |
| Dorzolamide | 15 | $247 | $16 |
| Timolol Maleate | 17 | $137 | $8 |
2015: 3 drugs
| Brimonidine | 20 | $996 | $50 |
| Latanoprost | 54 | $741 | $14 |
| Ketorolac Tromethamine | 11 | $215 | $20 |
Money from drug and device companies
$33 in 2025
| 2025 | 1 | 1 | None | $33 |
| 2024 | 2 | 3 | None | $1,057 |
| 2023 | 1 | 1 | None | $84 |
| 2022 | 3 | 3 | None | $249 |
| 2021 | 2 | 4 | None | $198 |
| 2020 | 2 | 3 | None | $180 |
| 2019 | 4 | 7 | None | $791 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Astellas Pharma Global Development | Izervay | $33 | 1 payment
|
See the published payment
| Astellas Pharma Global Development | Meals · 2025-08-02 | Izervay | $33 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,057
| Dutch Ophthalmic USA | Eva, Combined Machine | $840 | 1 payment
|
| Amgen | Tepezza | $217 | 2 payments
|
2023: $84
| Alimera Sciences | Iluvien | $84 | 1 payment
|
2022: $249
| Genentech | Vabysmo | $120 | 1 payment
|
| Alimera Sciences | Iluvien | $107 | 1 payment
|
| Alcon Vision | Rhopressa | $23 | 1 payment
|
2021: $198
| Regeneron Healthcare Solutions | Eylea | $161 | 2 payments
|
| Allergan | Ozurdex | $37 | 2 payments
|
2020: $180
| Alimera Sciences | Iluvien | $140 | 2 payments
|
| Regeneron Healthcare Solutions | Eylea | $40 | 1 payment
|
2019: $791
| Bausch & Lomb a division of Bausch Health US | Envista | $250 | 2 payments
|
| Alimera Sciences | Iluvien | $246 | 2 payments
|
| Novartis Pharmaceuticals | None | $244 | 2 payments
|
| Regeneron Healthcare Solutions | Eylea | $51 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 80.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1093058323
- Licence
- CA A147844California A147844: Current · expires 2028-08-31
- Trained
- Saint Louis University School of Medicine, 2013
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207W00000X (207W00000X); Federal specialty code 207WX0107X (207WX0107X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2013-04-04
- NPI last updated
- 2026-02-11
- NPI record certified
- 2026-02-11
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 9001 Wilshire Blvd Ste 301, Beverly Hills, CA, 90211 · 1245 Wilshire Blvd Ste 380, Los Angeles, CA, 90017 · 1450 San Pablo St Fl 4, Los Angeles, CA, 90033 · 301 S Fair Oaks Ave Ste 407, Pasadena, CA, 91105 · 3400 Lomita Blvd Ste 202, Torrance, CA, 90505